Last reviewed · How we verify
Blastic plasmacytoid dendritic cell neoplasm
Approved treatments
- Molecule 129 · Stemline Therapeeutics Inc
Tagraxofusp works by binding to CD123 on cancer cells, causing them to die.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Blastic plasmacytoid dendritic cell neoplasm patent landscape — cliff calendar, originator estates, attackable patents
- Blastic plasmacytoid dendritic cell neoplasm treatment landscape brief
- Blastic plasmacytoid dendritic cell neoplasm treatment updates RSS
Frequently asked questions about Blastic plasmacytoid dendritic cell neoplasm
What drugs treat Blastic plasmacytoid dendritic cell neoplasm?
Tracked treatments include Molecule 129.
What is the treatment for Blastic plasmacytoid dendritic cell neoplasm?
Standard treatment for Blastic plasmacytoid dendritic cell neoplasm includes Molecule 129. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Blastic plasmacytoid dendritic cell neoplasm patent cliff · Blastic plasmacytoid dendritic cell neoplasm CI report
- Treatment: Molecule 129 · Stemline Therapeeutics Inc
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing